Abstract
Edoxaban is a next new oral direct inhibitor of F Xa. The article presents overview of its effect compared to warfarin in the prevention of ischemic stroke and systemic embolisms in patients with non-valvular atrial fibrillation, or in the treatment and prevention of recurrence of deep vein thrombosis and pulmonary embolism.
Edoxaban is now registered for both of these indications in the Czech Republic. The review contains also notes on edoxaban use in clinical practice, including the procedure during haemorrhage and the possibility of its laboratory detection.